The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient perspectives on cytoreductive nephrectomy after CARMENA.
 
Dena Battle
Consulting or Advisory Role - Cardinal Health; Fresenius; Genentech; Hologic; Merck; Sanofi; Varian Medical Systems
 
Daniel J. George
Honoraria - Bayer; Exelixis; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Pfizer; Sanofi
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer (Inst)
 
Michael D. Staehler
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Exelixis; Incyte; Ipsen; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Exelixis; Ipsen; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis; Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer